Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Case of Pulmonary Sarcoidosis With Multiple Endobronchial Polypoid Structures and Partial Airway Obstruction.
J Investig Med High Impact Case Rep
January 2025
St. Joseph's University Medical Center, Paterson, NJ, USA.
We present a case of a 42-year-old male with sarcoidosis manifesting as endobronchial mass-like lesions, a rare and atypical presentation of the disease. Sarcoidosis typically involves the respiratory system, but its occurrence as endobronchial polyps mimicking malignancy is uncommon. The diagnosis was confirmed through bronchoscopy and biopsy, revealing non-caseating granulomas.
View Article and Find Full Text PDFExtrapulmonary sarcoidosis.
J Autoimmun
December 2024
Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States.
Article Synopsis
- - Sarcoidosis is a chronic inflammatory disease that arises in genetically susceptible individuals after exposure to certain antigens, primarily affecting the lungs but potentially impacting any organ, including the heart, nervous system, and eyes, which can lead to severe complications.
- - Diagnosis is typically easier when typical symptoms and biopsy findings are present, but it becomes more complex when symptoms manifest in areas outside the lungs without accompanying lung issues.
- - First-line treatment for sarcoidosis involves corticosteroids, while immunosuppressive or biologic medications are used for patients who do not respond to steroids or have refractory disease.
Factors Associated with Corticosteroid Adherence in Sarcoidosis.
Lung
December 2024
Department of Epidemiology and Biostatistics, College of Public Health, Temple University, Philadelphia, PA, USA.
Purpose: We measured corticosteroid medication adherence (CMA) in sarcoidosis patients and analyzed if demographic and clinical factors, beliefs about medications, corticosteroid side-effects, psychosocial status, and the doctor-patient relationship were associated with corticosteroid adherence.
Methods: Sarcoidosis patients receiving corticosteroids were eligible to participate. CMA was measured using the Medication Adherence Response Scale-10 (MARS-10), a validated patient reported outcome measure (PRO).
Neurosarcoidosis: Clinical, biological, and MRI presentation of central nervous system disease in a national multicenter cohort.
Brain Behav
September 2024
Service de Neurologie, Institut du Thorax et du Système Nerveux, CRC-SEP, CHU Nantes, Nantes Université, Nantes, France.
Introduction: Neurosarcoidosis (NS) is a systemic inflammatory granulomatous disease affecting of patients with sarcoidosis. Its diagnosis is difficult as there is no specific test for it. Because of its rarity, the management of NS has so far only been described in case series and short retrospective cohorts.
View Article and Find Full Text PDFGranulomatous myositis: characteristics and outcome from a monocentric retrospective cohort study.
Neuromuscul Disord
September 2024
Department of Internal Medicine, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Claude Bernard-Lyon 1, Lyon, France; Research on Healthcare Performance (RESHAPE), U129-INSERM, Université Claude Bernard-Lyon 1, Lyon, France. Electronic address:
Granulomatous myositis is a clinical-pathological entity, which has been rarely reported, mostly described in sarcoidosis. Currently, no clear and simple prognostic factor has been identified to predict granulomatous myositis evolution. The clinical, anatomopathological, imaging, and biological characteristics of 26 patients with granulomatous myositis were retrospectively collected to describe clinical presentation and outcomes of this condition.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!